These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 35967405)

  • 21. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
    Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
    Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A
    Tominaga K; Uchida T; Imakiire T; Itoh K; Shimazaki H; Nakanishi K; Kumagai H; Oshima N
    BMC Nephrol; 2018 May; 19(1):120. PubMed ID: 29792176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
    Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
    BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
    Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombotic thrombocytopenic purpura developed during the conservative treatment of anti-phospholipase A
    Iio R; Akiyama S; Mitsumoto K; Iwata Y; Okushima H; Shimada K; Ota N; Tomida K; Fushimi H; Shoji T; Matsumoto M; Hayashi T
    BMC Nephrol; 2020 Oct; 21(1):431. PubMed ID: 33046023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt HO; Tomas NM; Helmchen U; Panzer U; Stahl RA
    Nephrol Dial Transplant; 2015 Nov; 30(11):1862-9. PubMed ID: 26142398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy.
    Zhang C; Zhang M; Chen D; Ren Q; Xu W; Zeng C; Qin W; Liu Z
    J Clin Pathol; 2019 Oct; 72(10):705-711. PubMed ID: 31243053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. THSD7A-positive membranous nephropathy after kidney transplantation: A case report.
    Solà-Porta E; Buxeda A; Lop J; Naranjo-Hans D; Gimeno J; Lloveras-Rubio B; Pérez-Sáez MJ; Redondo-Pachón D; Crespo M
    Nefrologia (Engl Ed); 2023 Dec; 43 Suppl 2():85-90. PubMed ID: 36681516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.
    Lin JS; Wang DY; Mamlouk O; Glass WF; Abdelrahim M; Yee C; Abudayyeh A
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute chest pain and dyspnoea as clinical presentation of primary membranous nephropathy. A case report and literature review.
    Poggiali E; Borio G; Magnacavallo A; Vercelli A; Cervellin G
    Acta Biomed; 2022 Oct; 93(5):e2022216. PubMed ID: 36300242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitor therapy associated with IgA nephropathy: a case report and literature review.
    Chabannes M; Lisri Z; Lang S; Seibel J; Eberst G; Ducloux D; Pursun C; Durey MAD; Alyanakia MA; Felix S; Crepin T
    Front Immunol; 2024; 15():1393901. PubMed ID: 38807591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.